IDEXX Laboratories, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45168D1046
USD
717.47
-15.26 (-2.08%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About IDEXX Laboratories, Inc. stock-summary
stock-summary
IDEXX Laboratories, Inc.
Pharmaceuticals & Biotechnology
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.
Company Coordinates stock-summary
Company Details
1 Idexx Dr , WESTBROOK ME : 04092-2041
stock-summary
Tel: 1 207 5560300
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 175 Schemes (41.33%)

Foreign Institutions

Held by 469 Foreign Institutions (28.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Lawrence Kingsley
Independent Chairman of the Board
Mr. Jonathan Mazelsky
President, Chief Executive Officer, Director
Mr. Jonathan Ayers
Director
Mr. Bruce Claflin
Independent Director
Dr. Asha Collins
Independent Director
Dr. Stuart Essig
Independent Director
Dr. Rebecca Henderson
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,109 Million
(Quarterly Results - Jun 2025)
Net Profit:
294 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 66,543 Million (Large Cap)

stock-summary
P/E

60.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.66

stock-summary
Return on Equity

67.47%

stock-summary
Price to Book

45.61